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Available online 1 May 2014Antibiotic-resistant microorganisms continue to emerge
and spread.1,2 Antimicrobial resistance is one of the three
major challenges in patient safety. In 2011, the World
Health Organization designated “Combat antimicrobial
resistance” as the theme for World Health Day, stating “no
action today, no cure tomorrow.”3 We need to actively
confront the issue of antimicrobial resistance.
Antimicrobial resistance is both a threat and a chal-
lenge to the treatment of infectious diseases in Taiwan.
Based on the national database on antimicrobial resis-
tance from the Taiwan Nosocomial Infection Surveillance
System during the period 2003e2012, the proportion of
methicillin-resistant Staphylococcus aureus infections in
intensive care units in medical centers and regional hos-
pitals decreased from 89.2% to 69.9%; the proportion of
vancomycin-resistant enterococci infections increased
from 2.9% to 23.2%; the proportion of Enterobacteriaceae
isolates resistant to carbapenems increased from 1.4% to
8.1%; and the proportion of Acinetobacter baumannii
isolates resistant to imipenem or meropenem increased
from 17.2% to 72.8%.4
In response to the emergence of antimicrobial resis-
tance in pathogens encountered in hospitals and, more
recently, in the community, the Centers for Disease* Corresponding author. Flat 9, Number 6, Linsen South Road,
Zhongzheng District, Taipei City, Taiwan 10050, ROC.
E-mail address: fychang@cdc.gov.tw (F.-Y. Chang).
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1684-1182/Copyright ª 2014, Taiwan Society of Microbiology. PublishedControl, Taiwan (Taiwan CDC) has implemented a national
action plan to combat antimicrobial resistance5: the
antimicrobial management project from 2013 to 2015 for
preventing the emergence of resistant microorganisms and
decreasing health care-associated infections (HAIs). The
national action plan on antimicrobial resistance is a
multifaceted, multidisciplinary approach which works
through the implementation of antimicrobial stewardship
by hospitals, coordination and supervision, regular review
and allocation of resources, measuring performance, and
benchmarking (Fig.1). The phases of the national action
planeantimicrobial management project include a plan-
ning phase, an executive phase, and a policy evaluation
phase.Planning phase
The main intervention measures are the appropriate use of
antibiotics and infection control. The former consists of a
prospective audit with intervention and feedback, formu-
lary restriction and preauthorization, surveillance of anti-
microbial resistance and consumption, an effective health
information system, and education.6 The latter includes
hand hygiene, isolation and protection, audit and evalua-
tion, regional labeling, and antimicrobial resistance anal-
ysis. The expected achievements are a reduction in the
consumption of antimicrobial drugs, reduction in antimi-
crobial resistance, and a reduction in HAIs. The coreby Elsevier Taiwan LLC. All rights reserved.
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resistance include multidisciplinary professionals and
coordination.7 The roles for the national action
planeantimicrobial management program are given in the
following sections.
Role of the Taiwan CDC
The role of the Taiwan CDC is the coordination of policy
planning, management, and inspection for the national
action plan to combat antimicrobial resistance.
Role of the infectious diseases service
The role of the infectious diseases service is to coordinate
the establishment of the hospital antimicrobial management
mechanism and its strategic promotion in hospitals, moni-
toring HAIs, and implementing infection control measures.
Role of the pharmacy
The role of the pharmacy is the assessment of the appro-
priateness of prescriptions for antibiotic drugs, monitoring
a checklist of adverse drug reactions, and monitoring of
therapeutic drugs.
Role of the clinical microbiology service
The role of the clinical microbiology service is the assess-
ment of standard operating procedures for examinationsFigure 1. Infrastructure of the national action plaand the proposal of definite improvement plans, such as a
reduction in the defect rate and the rate of contamination
of specimens, and the use of rapid test kits or equipment to
provide fast and accurate test results.
Role of computer technology
Computer technology has a role in strengthening and inte-
grating the various information systems of consumption of
antimicrobial drugs, antimicrobial resistance, HAIs, and
clinical information of patients.
Executive phase
There are three levels for the implementation of the
executive phase8: a project management center, the
demonstration centers, and the participating hospitals.
Establishment of the project management center
Professional organizations are entrusted with developing
the project management center. The duties of the center
include the preparation of an antimicrobial management
toolkit and the assessment of the antimicrobial manage-
ment project, creating and analyzing the monitoring per-
formance indicators periodically, implementing external
audits and inspection, organizing the antibiotic manage-
ment forum, and the promotion of benchmarking and per-
formance competitions. Educating and training medical
professionals and the public, developing digital learningndantimicrobial management project in Taiwan.
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included.
Regional development of demonstration center for
management of antibiotic drugs
A total of seven demonstration centers have been selected
for the antimicrobial drug management project. These are
required to provide their own experience of antimicrobial
management through the exchange of experience and re-
sources and to help the project management center to
develop national technical documents. The upgrade of the
management capabilities of antibiotic drugs in each hospi-
tal are achieved by the evaluation and monitoring perfor-
mance indicators of this project, observations and learning
between hospitals, and the exchange of executive
experience.
Regional assessment and screening of participating
hospitals
A total of 55 hospitals have been selected for participa-
tion. The demonstration centers from each district are
responsible for understanding the basic status of partici-
pation, assisting in defining the cause of problems,
developing the program on the appropriate use of anti-
biotic drugs and infection control in accordance with the
characteristics of each different hospital. For hospitals
with poor performance on the execution of the program,
on-site visits and consultations are provided by the
demonstration centers.
Policy evaluation phase
The national action planeantimicrobial management proj-
ect was implemented in May 2013. The preliminary sur-
veillance using the first half-year of data showed that the
rate of antimicrobial resistance, antibiotics use, and the
rate of HAIs decreased. For example, the rate of antimi-
crobial resistance declined by 6.6%, within which the pro-
portion of Acinetobacter baumanni isolates resistant to
imipenem or meropenem decreased from 60.5% to 56.5%.
The total hospital antibiotic drug usage rates declined by
2.3%, from 1009 to 986 defined daily doses per 1,000 patient
days, and the rate of HAIs declined by 12.0%, from 2.5 to
2.2 per 1,000 patient days, from May 2013 to December
2013.
In conclusion, The effectiveness of the national action
plan on antimicrobial resistance could be achieved through
the promotion of an antimicrobial management program
and hospital implementation. The evidence database of
this program will be provided for the national health in-
surance payment, review and monitoring strategy, the
evaluation of hospital accreditation, the aggressive
involvement of a guaranteed global budget in national
health insurance, and the evaluation of standards in med-
ical centers in the future. Together, these will encourage
hospitals to focus on antimicrobial management and
enhance patient safety.
Antimicrobial resistance significantly increases
morbidity, mortality, and medical costs.9 Each year in theUSA, at least 2 million people acquire serious infections
from resistant microorganisms. At least 23,000 people die
each year as a direct result of these antibiotic-resistant
infections. The estimated extra medical costs of antimi-
crobial resistance are as high as $20 billion a year. The use
of antibiotic drugs is the single most important factor
leading to antibiotic resistance around the world. Up to 50%
of all the antibiotic drugs prescribed are inappropriate as
prescribed.10 The prevention of antimicrobial resistance is
not impossible to achieve. However, a reduction in the
spread of resistant microorganisms and an improvement in
the quality of medical care can be only achieved by mul-
tiple strategies with the cooperation of governments, in-
stitutions, professionals, and the public.
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